Sino Biopharmaceutical's Total Assets for the quarter that ended in Jun. 2024 was HK$71,809 Mil.
Warning Sign:
If a company builds assets at 23.9% a year, faster than its revenue growth rate of 3.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Sino Biopharmaceutical's average Total Assets Growth Rate was 5.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 14.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 23.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 25.50% per year.
During the past 13 years, Sino Biopharmaceutical's highest 3-Year average Total Assets Growth Rate was 52.70%. The lowest was 5.80%. And the median was 29.40%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sino Biopharmaceutical's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (HKSE:01177) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Jun. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sino Biopharmaceutical's Asset Turnover for the quarter that ended in Jun. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sino Biopharmaceutical Total Assets Related Terms
Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01177 has been successfully added to your 